TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01994525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfRAS
Description: Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfRAS
Description: Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfRAS
Description: Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by the bite of noninfected Anopheles stephensi mosquitoes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by the bite of noninfected Anopheles stephensi mosquitoes

Intervention type: OTHER
Group type: OTHER
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: OTHER
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Challenge
Description: 5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
Study: NCT00733616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOX: Docetaxel, oxaliplatin, Capecitabine
Description: * Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)
Study: NCT04015232

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INTP5
Description: INTP5, a pegfilgrastim biosimilar to US Neulasta.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta: FDA approved pegfilgrastim innovator product.
Study: NCT04483583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
Study: NCT03473314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide gas at 160ppm
Description: Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
Study: NCT02658084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Administered as an intravenous infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Administered as an intravenous infusion on Day 1 of every 21-day cycle.
Study: NCT01880073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemVue device
Description: The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
Study: NCT02933775

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CD19 T cells
Description: Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day×4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2/day×2 days
Study: NCT01153984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg oral doses will be administered daily.
Study: NCT02857842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study: NCT03247556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg SPN-812
Description: 600mg SPN-812 was administered once daily and compared to Placebo
Study: NCT04148313

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT03057392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: participants will sit in a 34-35C while receive dialysis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham session
Description: dialysis while sitting in the dialysis chair
Study: NCT02495558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex Cough Test
Description: Peak of Cough Expiratory Flow of the reflex cough
Study: NCT04614961

Intervention type: OTHER
Intervention: Lifestyle therapy - individual
Description: Individual therapy

Intervention type: OTHER
Intervention: Lifestyle therapy - group
Description: Group therapy

Intervention type: OTHER
Intervention: Medical therapy
Description: Medical therapy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical and endoscopic therapy
Study: NCT03413046

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral and bone marrow sampling
Description: We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral and bone marrow sampling
Description: We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
Study: NCT03654196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301(Experimental)
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umkamin(Active Comparator)
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
Study: NCT03717064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
Study: NCT00430079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanidazole
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00337077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT02305758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: 200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRI
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil infusion
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil infusion
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
Study: NCT05249413

Intervention type: PROCEDURE
Intervention: Early 23-gauge pars-plana vitrectomy
Description: pars-plana vitrectomy for management of acute post-operative endophthalmitis.
Study: NCT03831048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Heart System
Description: Preserving and assessing donor after circulatory death hearts for transplant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Storage
Description: Active comparator intervention
Study: NCT03102580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OA Care Plan
Description: Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
Study: NCT02761980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 250 mg / Acetaminophen 500 mg
Description: Ibuprofen 250 mg / Acetaminophen 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 250 mg
Description: Ibuprofen 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500 mg
Description: 1 APAP 500 mg caplet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00826774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling
Description: These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling
Description: These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
Study: NCT00458900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV and enteral administration of moxifloxacin
Description: IV and enteral administration of moxifloxacin
Study: NCT01135641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Study: NCT04590443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study: NCT00650000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Tablets 200 mg
Description: 200mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provigil® Tablets 200 mg
Description: 200mg, single dose fasting
Study: NCT00406848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
Study: NCT00583700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E (Over-the-counter) 400 I.U. once daily
Study: NCT00930488

Intervention type: DRUG
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Study: NCT05282160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epino
Description: The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
Study: NCT00977106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: single iv infusion 8 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: iv infusion 8mg/kg every 4 weeks for 11 months
Study: NCT01522352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement by bioprosthesis
Description: Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
Study: NCT03231670

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: 5ml blood will be taken in addition to standard sampling
Study: NCT01894178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker Flex-Tip® tracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portex® Tracheal Tube
Study: NCT01720082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic appendectomy
Description: A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport laparoscopic appendectomy
Description: Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
Study: NCT01179880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005
Description: Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for each step
Study: NCT03030066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1001b
Description: Generic not assigned
Study: NCT04182737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgM-enriched polyclonal immunoglobulins titer-based treatment
Description: Immunoglobulins will be administered in a personalized dose based on serum IgM-titers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IgM-enriched polyclonal immunoglobulins Flat treatment
Description: Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
Study: NCT03536117

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
Study: NCT00256672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam
Description: TLSO back brace, Flex-Foam (Posterior Opening)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam
Description: TLSO back brace, Flex-Foam (Posterior Opening)
Study: NCT04149756

Intervention type: OTHER
Intervention: observation of weight after 6months
Description: This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. .